ArticleFrontiers in oncology2026

Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib.

Junqi Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.